Publications
5539 Results
- Journal / Conference
- Gynecologic Oncology Jun;173:130-137
- Year
- 2023
- Research Committee(s)
- Gynecologic
- PMID
- PMID37148580
- PMC
- PMC10414765
- Study Number(s)
- G0182
The effect of old age treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG Oncology Group/Gynecologic Oncology Group study
- Journal / Conference
- Lancet Sep 23;402(10407):1043-1051
- Year
- 2023
- Research Committee(s)
- Genitourinary
- PMID
- PMID37524096
- PMC
- PMC10622111
- Study Number(s)
- S0931
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
- Journal / Conference
- Cancers (Basel) Apr 29;15(9):2561
- Year
- 2023
- Research Committee(s)
- Melanoma
- PMID
- PMID37174027
- PMC
- PMC10177189
- Study Number(s)
- CTSU/E1609, S1404
Granulomatous and Sarcoid-like Immune Related Adverse Events Following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and A Literature Review
- Journal / Conference
- Lancet Gastroenterology and Hepatology Aug 1;S2468-1253(23)00191-7
- Year
- 2023
- Research Committee(s)
- Palliative and End of Life Care
- PMID
- PMID37541263
- PMC
- PMC10530384
- Study Number(s)
- S1316
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 6532); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 17; abstr LBA2); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), plenary session - oral
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/N1048
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5048); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): results from the Phase III SWOG S1216 trial of androgen deprivation +/- orteronel
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 4508); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1011
SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS4191); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A021804
A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 7500); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
- Research Committee(s)
- Leukemia